OTC Continuous Glucose Monitoring Market Size & Share 2026-2035

OTC Continuous Glucose Monitoring Market Size

The global OTC continuous glucose monitoring market was valued at USD 528.2 million in 2025. The market is expected to reach USD 613 million in 2026 to USD 2.5 billion in 2035, growing at a CAGR of 17.1% during the forecast period, according to the latest report published by Global Market Insights Inc. OTC CGM includes a continuous glucose monitoring system that is available for purchase and use without a prescription from a healthcare professional. While continuous glucose monitoring (CGM) devices are prevalent in diabetes management, the application of OTC continuous for monitoring preventive health goes beyond the diabetes population.

Over-the-counter continuous glucose monitoring (CGM) devices are wearable medical devices designed to track glucose levels in real time without the need for a prescription. These systems are increasingly being adopted not only by diabetic patients but also by prediabetic individuals and health-conscious consumers seeking proactive metabolic health management. OTC CGMs eliminate barriers to access, enabling broader population use and supporting preventive healthcare approaches.

The major players in the global market are Abbott, Dexcom, and Sinocare. These companies maintain their competitive position through ongoing product innovation, global market presence, and substantial investment in the market.

The market increased from USD 263.3 million in 2022 to USD 370.7 million in 2024, registering a historical growth rate of 18.6%. This growth was seen due to the increasing prevalence of diabetes and prediabetes globally, rising awareness of continuous glucose tracking, and increasing consumer interest in personalized health monitoring. In addition, advancements in sensor technology, smartphone integration, and non-invasive or minimally invasive solutions are further accelerating adoption.

Furthermore, the increasing adoption of over-the-counter continuous glucose monitoring (CGM) devices is being driven by continuous technological advancements and growing consumer interest in proactive health management. The development of more precise sensors, compact form factors, extended wear durations, and seamless integration with smartphones and wearable devices has significantly enhanced the appeal of OTC CGMs among the general population. Notably, advancements in sensor accuracy, such as achieving a mean absolute relative difference (MARD) of less than 10% and extended wear times of up to 14 days, have markedly improved the reliability, convenience, and usability of these devices, making them suitable for both diabetic and non-diabetic users.

OTC Continuous Glucose Monitoring Market Trends

Several trends are shaping the OTC Continuous Glucose Monitoring (CGM) market. The growing adoption of CGM devices beyond traditional diabetes management is significantly expanding the market scope. OTC CGMs are increasingly being used by fitness enthusiasts, biohackers, and individuals focused on metabolic health, stress management, and longevity, driving their transition from clinical tools to consumer wellness solutions. These devices enable users to track how diet, exercise, and lifestyle behaviors impact glucose levels, making them a key component of personalized health optimization.

• Rising demand for health optimization and lifestyle monitoring represents another key trend influencing market growth. Consumers are increasingly leveraging CGM data to make informed decisions about nutrition, physical activity, and overall wellness. This shift toward data-driven health management and preventive care is making CGMs an essential tool in the broader consumer health ecosystem, particularly as metabolic health becomes a central focus area in chronic disease prevention.
• Advancements in non-invasive and minimally invasive technologies are further shaping market evolution. Innovations aimed at reducing or eliminating the need for skin punctures, such as optical sensing and transdermal monitoring technologies, are improving user comfort and experience. These developments are addressing key barriers associated with traditional CGMs and are expected to significantly broaden adoption among wellness-focused consumers seeking convenient and low-discomfort monitoring solutions.
• Additionally, integration of artificial intelligence (AI) and advanced analytics is transforming OTC CGM platforms. AI-driven algorithms analyze continuous glucose data to identify patterns, predict glucose fluctuations, and provide real-time recommendations. This enables users to proactively manage potential hyperglycemic or hypoglycemic events and optimize lifestyle decisions, thereby enhancing the clinical and functional value of CGM devices.

OTC Continuous Glucose Monitoring Market Analysis

Based on component, the market is segmented into sensors and platforms/apps. The sensors segment has asserted its dominance in the market by securing a significant market share of 91% in 2025. The segment is expected to reach USD 2.3 billion by 2035, growing at a CAGR of 17.2% during the forecast period.

• The increasing demand for compact, user-friendly, and wearable health monitoring devices is a key factor driving the dominance of the sensors segment in the OTC CGM market. Consumers are increasingly preferring devices that are small, lightweight, comfortable, and minimally intrusive, making advanced sensor technologies the core component of CGM systems. This shift toward convenience and continuous monitoring has significantly boosted sensor adoption across both diabetic and non-diabetic user groups.
• Ongoing innovation in sensor materials and design is further supporting segment expansion. The use of advanced materials such as graphene, flexible polymers, and stretchable electronics is enhancing sensor performance by improving skin adaptability, durability, and measurement accuracy. Additionally, next-generation devices such as Dexcom Stelo and Abbott Libre Rio feature smaller, lighter sensors, reinforcing user comfort and long-term wearability.
• In addition, advancements in connectivity and digital integration are strengthening the value of sensors within the CGM ecosystem. Modern sensors are increasingly designed to integrate seamlessly with smartphones, wearable devices, and AI-driven platforms, enabling real-time glucose monitoring, efficient data transmission, and low power consumption. This connectivity supports cloud-based analytics and personalized health insights, enhancing usability and expanding applications in preventive health and wellness monitoring.
• The platforms/apps segment accounted for USD 47.5 million in 2025 and is projected to expand at a CAGR of 15.6% from 2026 to 2035. The segmental growth is driven by increasing demand for AI-powered analytics, personalized health insights, and integration with wearable ecosystems, enabling users to interpret glucose data effectively and manage metabolic health.

Based on consumer type, the OTC continuous glucose monitoring market is segmented into non-diabetic health enthusiasts, pre-diabetic and at-risk individuals, and other consumer types. The pre-diabetic and at-risk individuals segment dominated the market in 2025.

• The rising global prevalence of prediabetes and impaired glucose tolerance is a key factor driving the dominance of this segment in the OTC CGM market. A significant proportion of the population is at risk of developing type 2 diabetes due to lifestyle factors such as poor diet, obesity, and physical inactivity, increasing the demand for accessible tools that support early detection and continuous metabolic monitoring.
• The growing shift toward preventive healthcare and proactive disease management is further supporting segment growth. OTC CGMs enable pre-diabetic and at-risk individuals to gain real-time insights into how diet, physical activity, and stress impact glucose levels, encouraging healthier lifestyle choices and reducing the likelihood of disease progression.
• Additionally, increasing awareness and adoption of self-monitoring and digital health solutions have enhanced the use of CGMs in this population. These devices empower individuals with actionable data, helping them identify metabolic imbalances early and take timely corrective measures, thereby preventing complications and lowering long-term healthcare costs. This rising focus on early intervention and personalized health management continues to reinforce the segment’s dominance in the overall market.
• The non-diabetic health enthusiasts segment accounted for USD 197.4 million in 2025 and is projected to grow at a CAGR of 17.5% over the forecast period. Growth is primarily driven by the increasing consumer focus on fitness, metabolic optimization, and personalized wellness, with individuals leveraging OTC CGMs to monitor real-time glucose responses to diet, exercise, sleep, and stress, thereby supporting data-driven lifestyle modifications and expanding the adoption of CGMs beyond traditional medical use.

Based on distribution channel, the OTC continuous glucose monitoring market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. The e-commerce segment dominated the market with a revenue share of 56.1% in 2025.

• The rising adoption of online platforms for health and wellness products is further supporting segment growth. E-commerce enables consumers to purchase OTC CGMs conveniently while maintaining privacy, along with access to detailed product information, user reviews, and digital engagement offered by manufacturers and platform providers.
• Additionally, the expansion of subscription-based models and home delivery services has strengthened adoption, allowing users to receive continuous sensor supplies through recurring shipments. This is particularly beneficial for users in remote or underserved areas with limited access to physical pharmacies.
• Moreover, e-commerce platforms offer a wider range of device options, bundled services, and personalized solutions, enabling consumers to select products aligned with their health and wellness goals. This enhanced accessibility, convenience, and customization continue to drive strong revenue growth in the segment and reinforce its market dominance.
• The hospital pharmacies segment accounted for a 9.2% revenue share in 2025 and is anticipated to grow at a steady pace over the forecast period. Growth in this segment is driven by the continued reliance on hospital-based distribution channels for initial CGM adoption, particularly for individuals transitioning from prescription-based systems to OTC usage.
• The retail pharmacies segment accounted for a 34.7% revenue share in 2025 and is expected to witness stable growth over the forecast period. Growth is primarily supported by increasing availability of OTC CGM devices in pharmacy chains and drugstores, enabling convenient access for walk-in consumers.

North America OTC Continuous Glucose Monitoring Market

North America dominated the market with the highest market share of 53.9% in 2025.

• The U.S. market was valued at USD 109.8 million and USD 123.8 million in 2022 and 2023, respectively. The market size reached USD 160.2 million in 2025, growing from USD 140 million in 2024, and is anticipated to grow at a CAGR of 16.1% from 2026 to 2035.
• North America, particularly the U.S., represents a significant market for OTC continuous glucose monitoring (CGM) devices, supported by the growing consumer shift toward preventive health, metabolic optimization, and personalized wellness. Increasing adoption among non-diabetic individuals, including fitness enthusiasts and health-conscious consumers, is driving demand for CGMs as lifestyle tools rather than purely medical devices, significantly expanding the market base.
• The region benefits from a progressive regulatory landscape and a strong digital health ecosystem, which is accelerating market growth. The U.S. Food and Drug Administration (FDA) has taken steps to ease access to CGMs and support OTC availability, as seen with recent approvals such as Dexcom Stelo. These developments reduce barriers to entry for manufacturers while enhancing consumer confidence and encouraging wider adoption of self-monitoring solutions.
• Additionally, the widespread use of smartphones and high adoption of wearable technologies in the U.S. is supporting seamless integration of CGMs with digital health applications and connected devices. The strong presence of direct-to-consumer platforms, personalized health apps, and subscription-based models, combined with early adoption by tech-savvy consumers, continues to drive sustained market growth and positions North America as a leading and high-value region in the OTC CGM market.

Europe OTC Continuous Glucose Monitoring Market

Europe market accounted for USD 123.4 million in 2025 and is anticipated to show lucrative growth over the forecast period.

• Europe represents a significant and steadily growing market for OTC continuous glucose monitoring (CGM) devices, supported by the rising prevalence of diabetes and prediabetes across the region. Increasing cases driven by ageing populations and lifestyle-related factors have created strong demand for accessible and user-friendly metabolic monitoring tools, with OTC CGMs enabling early identification and management of glucose fluctuations without frequent clinical intervention.
• The region benefits from well-developed public healthcare systems and a strong focus on preventive care, which is encouraging the adoption of OTC CGMs as part of broader chronic disease management strategies. These devices align with healthcare priorities centered on early intervention, reducing long-term treatment costs, and minimizing the burden on healthcare infrastructure, particularly in countries facing rising patient loads and resource constraints.
• Additionally, growing consumer interest in personalized health and wellness is driving adoption across European markets. Health-conscious individuals are increasingly using OTC CGMs to monitor real-time glucose responses to diet, exercise, and stress, supporting customized nutrition plans and lifestyle modifications. Combined with increasing awareness of metabolic health, self-management approaches promoted by healthcare systems, and integration with digital health applications and wearable devices, these factors are positioning Europe as a key growth region in the OTC CGM market.

Asia Pacific OTC Continuous Glucose Monitoring Market

The Asia Pacific market is anticipated to grow significantly during the analysis timeframe.

• Asia Pacific represents a rapidly growing market for OTC continuous glucose monitoring (CGM) devices, driven by the rising prevalence of prediabetes and metabolic disorders across the region. Rapid urbanization, changing dietary patterns, and increasingly sedentary lifestyles, particularly among South and East Asian populations, have significantly increased the at-risk population, creating strong demand for accessible tools that support early detection and continuous glucose monitoring.
• Healthcare systems across the region are facing increasing pressure from the growing burden of chronic diseases, encouraging the adoption of OTC CGMs as cost-effective, non-invasive solutions for early intervention and self-management. These devices enable individuals to monitor glucose levels in real time without frequent clinical visits, helping to reduce strain on healthcare infrastructure while promoting proactive disease prevention.
• Additionally, rising health awareness and adoption of personal wellness tracking tools are accelerating market growth. Consumers, particularly in urban centers, are increasingly focused on managing weight, improving insulin sensitivity, and optimizing overall metabolic health. OTC CGMs are being used as real-time biofeedback tools, allowing users to understand how diet, exercise, and stress impact their glucose levels. This growing health literacy and willingness to adopt digital health solutions are significantly driving demand and positioning Asia Pacific as a high-growth region in the OTC CGM market.

Rest of the World OTC Continuous Glucose Monitoring Market

The Rest of the World market is experiencing robust growth over the analysis timeframe.

• Rest of the World represents an emerging and high-growth market for OTC continuous glucose monitoring (CGM) devices, driven by the rising burden of type 2 diabetes, obesity, and prediabetes across Latin America, the Middle East, and Africa. Countries such as Brazil and Saudi Arabia are witnessing increasing prevalence of metabolic disorders due to lifestyle changes, poor dietary habits, and sedentary behavior, creating strong demand for accessible and preventive health monitoring solutions.
• In Latin America, particularly Brazil, the growing number of undiagnosed and pre-diabetic individuals is accelerating interest in OTC CGMs as tools for early detection, lifestyle tracking, and preventive care. Limited access to specialized healthcare professionals, especially in rural and underserved regions, is further driving adoption, as OTC CGMs provide a decentralized, patient-driven approach to glucose monitoring without requiring frequent clinical visits.
• Additionally, in the Middle East and Africa, high rates of obesity and diabetes, combined with increasing awareness of metabolic health, are supporting the uptake of OTC CGMs among at-risk populations. These devices offer a non-invasive, convenient, and prescription-free solution for continuous monitoring, enabling users to manage their health proactively. Improving digital health awareness, growing smartphone penetration, and rising demand for self-monitoring tools are expected to further strengthen market growth across the Rest of the World region.

OTC Continuous Glucose Monitoring Market Share

The global OTC continuous glucose monitoring (CGM) market is characterized by high and rapidly evolving competition, driven by continuous advancements in sensor technology, expansion of digital health ecosystems, and increasing focus on consumer-centric wellness solutions. Market participants are actively investing in the development of high-accuracy sensors, longer wear-duration devices, AI-enabled analytics, and seamless integration with smartphones and wearable technologies to enhance user experience and broaden adoption beyond traditional diabetic care.

Key players in the market include Abbott, Dexcom, and Sinocare, which collectively account for approximately ~91% of the total global market share. These companies maintain strong competitive positions through robust product portfolios, global distribution capabilities, and continuous innovation in CGM systems. Abbott and Dexcom lead in technology advancement and global penetration, while Sinocare strengthens competition through cost-effective offerings and expanding presence in emerging markets. Significant investments in research and development have enabled these companies to introduce next-generation CGM solutions with improved accuracy, compact designs, and enhanced digital integration, supporting both clinical and consumer use cases.

In addition to these leading players, several digital health platforms and emerging companies are contributing to market competition by offering subscription-based services, personalized analytics, and lifestyle coaching integrated with CGM devices. These players primarily focus on the wellness and preventive health segment, targeting non-diabetic consumers through direct-to-consumer models.

OTC Continuous Glucose Monitoring Market Companies

A few of the prominent players operating in the OTC continuous glucose monitoring industry include:

• Abbott
• Dexcom
• January AI
• Levels Health
• Limbo (Vitals in View)
• Nutrisense
• Sinocare
• Supersapiens
• Ultrahuman Healthcare
• Veri
• Zoe
• Sinocare
• Sinocare is a prominent player in the OTC CGM market, supported by its cost-effective glucose monitoring solutions and expanding CGM product portfolio, particularly across Asia. The company focuses on affordability, accessibility, and localized manufacturing advantages, enabling broader adoption among price-sensitive consumers.
• Nutrisense
• Nutrisense has established a strong position in the OTC CGM market through its integrated digital health platform combining CGM devices with personalized nutrition coaching and analytics. The company’s strength lies in its ability to translate glucose data into actionable lifestyle recommendations, supported by expert guidance and app-based insights.
• Ultrahuman Healthcare
• Ultrahuman Healthcare holds a notable position in the OTC CGM market through its performance-driven and metabolic fitness-focused platform, targeting health-conscious and fitness-oriented consumers. The company integrates CGM data with its Ultrahuman app ecosystem, offering insights related to metabolism, recovery, sleep, and activity.

OTC Continuous Glucose Monitoring Industry News:

• In September 2024, Abbott introduced its Lingo continuous glucose monitoring (CGM) wearable targeted at health‑conscious consumers, enabling individuals to track glucose levels without requiring prior medical approval. This launch expands Abbott’s CGM portfolio into the consumer wellness segment, supporting broader adoption among non‑diabetic users and strengthening the company’s positioning in the rapidly evolving OTC and wearable health technology market.
• In June 2024, Abbott received U.S. Food and Drug Administration (FDA) clearance for its two over‑the‑counter continuous glucose monitoring (CGM) systems, Lingo and Libre Rio, based on its FreeStyle Libre technology platform. This regulatory milestone enables non-prescription access to CGM devices, expands the company’s reach beyond traditional diabetes care, and enhances Abbott’s competitiveness in the growing OTC CGM and consumer health monitoring industry.

The OTC continuous glucose monitoring market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Component

• Sensors
• Platforms/Apps

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• E-commerce

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Rest of World